Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$22.66 USD
+0.45 (2.03%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.60 -0.06 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.56 | $60.00 | $30.00 | 96.13% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Bicycle Therapeutics PLC Sponsored ADR comes to $43.56. The forecasts range from a low of $30.00 to a high of $60.00. The average price target represents an increase of 96.13% from the last closing price of $22.21.
Analyst Price Targets (9 )
Broker Rating
Bicycle Therapeutics PLC Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.25 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 83.33% and 8.33% of all recommendations. A month ago, Strong Buy made up 83.33%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 10 | 10 | 10 | 10 | 10 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/3/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
5/3/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
5/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/2/2024 | SVB Securities | Jonathan W Chang | Strong Buy | Strong Buy |
4/10/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Tara Bancroft | Strong Buy | Strong Buy |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/22/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
2/21/2024 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
12/20/2023 | JMP Securities | Reni Benjamin | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 12 |
Average Target Price | $43.56 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | -1.10 |